Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd. We are a global pharmaceutical company committed to providing affordable & innovative medicines. Dr. Reddy’s Laboratories Ltd.

(BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major the

rapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first
Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Dr. Reddy’s does not collect nor does it require you to share any personal data or personal information, towards your access to or participation in the Facebook event organised by it. You are advised to not disclose any personally identifiable or confidential or non-public information on social media; you are personally responsible for any data that you may decide to share or post on any social media including on this page and Dr. Reddy’s owes no duty or obligation or liability to you or to any other person for the same. All participants on this Facebook event are required to behave with courtesy to others and to not post any offensive/objectionable messages or to intrude into any other person’s rights of privacy.

31/05/2026

The road between quitting and abstinence is more complex than we think. The journey is rarely linear and often misunderstood. It calls for a shift from judgement to support. When we don’t pass a verdict, it creates space for compassion and empathy beyond tokenism. This World No-Tobacco Day lets traverse that journey together.

30/05/2026

Marking the 25th anniversary of Dr. Reddy’s Laboratories’ NYSE listing (RDY), our Chairman Satish Reddy rang The Closing Bell® at the New York Stock Exchange today, joined by Deepti Reddy, Vishal Reddy, Erez Israeli, M.V. Narasimham, M.V. Ramana, Milan Kalawadia, Penny Wan, K. Randhir Singh, Arun M. Kumar, Sridhar Iyer, Aishwarya Sitharam,
C. Swaminathan, Stephen Peterson, and Candice Teruszkin

Source: NYSE

We are all set and ready to engage. Visit Dr. Reddy’s at Booth 10092 at   to see how we are advancing access, impact, an...
29/05/2026

We are all set and ready to engage. Visit Dr. Reddy’s at Booth 10092 at to see how we are advancing access, impact, and the future of oncology.

We were at the Nasdaq Opening Bell ceremony in Times Square, New York, on May 26, 2026. The invitation followed recent r...
29/05/2026

We were at the Nasdaq Opening Bell ceremony in Times Square, New York, on May 26, 2026. The invitation followed recent recognition of our corporate governance by IiAS, BSE, and the International Finance Corporation (IFC).

We were at the Nasdaq Opening Bell ceremony in Times Square, New York, on May 26, 2026. The invitation followed recent r...
29/05/2026

We were at the Nasdaq Opening Bell ceremony in Times Square, New York, on May 26, 2026. The invitation followed recent recognition of our corporate governance by Institutional Investor Advisory Services (IiAS) , Bombay Stock Exchange , and the International Finance Corporation (IFC)



Our team will be attending the Jefferies Global Healthcare Conference in New York from 2nd to 4th June and the BIO Inter...
26/05/2026

Our team will be attending the Jefferies Global Healthcare Conference in New York from 2nd to 4th June and the BIO International Convention in San Diego from 22nd to 25th June, where we will be meeting partners who share our commitment to bringing innovative medicines and therapies to more patients.

We are focused on late-stage (Phase 2+) oncology and specialty therapies, with a mission to accelerate affordable access for patients. We look forward to connecting and collaborating.

To schedule a meeting, please write to: [email protected]

Join us at  .Visit Booth 10092 to meet our team and collaborate on driving meaningful progress in oncology.
22/05/2026

Join us at .

Visit Booth 10092 to meet our team and collaborate on driving meaningful progress in oncology.

With the launch of our oral semaglutide biosimilar, Obeda® tablets, we are broadening our GLP‑1 portfolio to offer more ...
20/05/2026

With the launch of our oral semaglutide biosimilar, Obeda® tablets, we are broadening our GLP‑1 portfolio to offer more choice and flexibility for patients. Oral semaglutide, as a convenient and flexible option, may support earlier treatment initiation, improve adherence, and help reduce the risk of long-term complications.

More about the launch in the press release, linked in the first comment.

With the launch of our generic Semaglutide Injection in Canada, we are among the first companies to enter the market, en...
16/05/2026

With the launch of our generic Semaglutide Injection in Canada, we are among the first companies to enter the market, enabling timely access to an important treatment option for people living with diabetes.

More in our press release – link in the first comment.

Join us at   as we share updates from Dr. Reddy’s oncology portfolio.See what’s new and stay tuned for highlights throug...
15/05/2026

Join us at as we share updates from Dr. Reddy’s oncology portfolio.

See what’s new and stay tuned for highlights throughout the congress.

Address

Dr. Reddy's Laboratories Limited (Corporate Office), Door No 8-2-337, Road No 3, Banjara Hills
Hyderabad
500034

Alerts

Be the first to know and let us send you an email when Dr. Reddy's Laboratories Ltd. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share